Fortis Healthcare (FORTIS) investor relations material

Executive summary

• Consolidated Q1 FY27 revenue grew 17.5% year-over-year to INR 2,545 crore, with hospital revenue up 19% and diagnostics up 10.2%.

• Operating EBITDA pre-ESOP rose 15.8% to INR 568 crore, margin at 22.3%; PAT before exceptionals up 13.6% to INR 263 crore.

• Recent acquisitions in Punjab, Bengaluru, and Delhi NCR contributed to growth; 100 new beds added via greenfield expansion.

• International business revenue increased 13.3% year-over-year, now 8% of total revenue.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed by the Board and statutory auditors, with no material misstatements identified.

Financial highlights

• Hospital business revenue reached INR 2,187 crore (+19% YoY); diagnostics gross revenue INR 407 crore (+10.2% YoY).

• Hospital operating EBITDA at INR 471 crore (margin 21.5%); diagnostics EBITDA margin improved to 23.9%.

• Net debt at INR 2,233 crore; net debt-to-EBITDA ratio 1.01x (vs 0.92x YoY), increase due to acquisitions.

• Consolidated net profit for Q1 FY27 was ₹27,280 lacs, compared to ₹26,678 lacs in Q1 FY26.

• Basic and diluted EPS for Q1 FY27 were ₹0.63 (standalone) and ₹3.53 (consolidated).

Outlook and guidance

• Margin guidance maintained at 25% EBITDA by FY28, including ESOP costs, driven by brownfield expansions and operational improvements.

• Diagnostic business expects 12%-13% revenue growth and 24%-25% EBITDA margin over the next two years.

• Continued focus on cluster-based expansion, with selective entry into new markets via O&M agreements.

• Inorganic growth opportunities under evaluation, primarily in existing clusters.

• The Board recommended a final dividend of ₹1.00 per equity share for FY26, subject to shareholder approval.